Investor Relations

SEC Filings

  o View CEL-SCI's SEC Filings  
       

Stock Quotes

  o NYSE AMEX: CVM  

Press Releases

  o Press Releases  
  JANUARY 26, 2012
NEW STORY CEL- SCI Corporation to Raise $5.76 Million in Registered Direct Offering
  JANUARY 20, 2012
NEW STORY CEL- SCI Corporation Releases Letter to Shareholders
  DECEMBER 27, 2011
NEW STORY CEL- SCI Corporation Authorizes Expansion of Phase III Clinical Trial to an Additional 4 European Countries
  DECEMBER 23, 2011
NEW STORY CEL-SCI Corporation Announces Fiscal 2011 Financial Results
  DECEMBER 7, 2011
NEW STORY CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)
  NOVEMBER 2, 2011
NEW STORY CEL- SCI Corporation Updates Phase III Clinical Activities for Investigational Cancer Therapy Multikine (Leukocyte Interleukin, Injection)
  OCTOBER 7, 2011
NEW STORY CEL-SCI Corporation Announces the Closing of Its $4 Million Registered Direct Offering of Common Stock and Warrants
 

Investor Relations Contact

   

Gavin de Windt
Phone: +1 703-506-9460
E-mail: gdewindt@cel-sci.com

 

 

Research &
Clinical Trials

 

  

SEC Filings